Sortina Pharma AB today announces a financing led by the venture capital fund Eir Ventures and with GU Ventures, to unlock the potential of proprietary anti- sortilin cancer therapy to cure aggressive cancer.
The founders of Sortina Pharma, Professor Göran Landberg and lead scientist Sara Rhost comment:
“Our goal is to improve today ́s cancer treatment by launching an entirely novel cancer therapy that specifically will inhibit cancer spread and metastasis and thereby profoundly improving life for cancer patients. This first financing is an important step and will enable us to advance our lead generation program towards clinical testing, strengthen the management team and leverage the highly experienced venture and biotech expertise of Eir Ventures, as we move to the next stage of growth”.
Magnus Persson, MD, PhD and Founding Partner of Eir Ventures, comment:
“Sortina Pharma is an excellent example of the vibrant innovation power of Nordic academia and the Company has the potential to have a profound impact on cancer therapy with its unique approach of inhibiting sortilin signaling. We are proud to support the team bringing Sortina Pharma forward”.